Navigation Links
Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2011 Results
Date:2/27/2012

nses increased $19.9 million, or 242%, to $28.1 million for the three months ended December 31, 2011, from $8.2 million for the three months ended December 31, 2010. The higher expenses for the three months ended December 31, 2011 were primarily due to increased selling and marketing expenses associated with the full commercial launch of KRYSTEXXA.

Interest expense on the Company's convertible notes was $4.3 million for the three months ended December 31, 2011.

Conference Call and WebcastThe Company will host a live conference call and webcast beginning at 9:00 a.m. Eastern Time on February 27, 2012 to discuss these results and to answer questions. To participate by telephone, please dial:Domestic:

866-393-1565International:

253-237-1151Conference ID:

49538226The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on February 27, 2012 through 12:00 a.m. Eastern Time on March 7, 2012 by dialing:

Domestic:

855-859-2056International:

404-537-3406Conference ID:

49538226ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign paten
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
2. Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
5. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
6. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
7. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
8. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
10. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, ... is scheduled to present a corporate overview and update at ... Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 ... New York . A live ... investor relations section of Arena,s website at www.arenapharm.com . ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... N.J., March 8, 2012  Janssen Research & Development, ... Phase 3 study of ZYTIGA® (abiraterone acetate) plus ... symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) ... Study COU-AA-302 is an international, randomized, double-blind, placebo ...
... AMSTERDAM, March 8, 2012  Leading events organiser UBM Live ... announced an addition to the CPhI Japan events line-up ... Sight Exhibition Centre from 21-23 March, 2012. The Pharmatech ... technology for the Pharma, biopharma, veterinary and medical industries, ...
Cached Medicine Technology:Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 3Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 4Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 5Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 6New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3
(Date:11/26/2014)... Loffler Companies has been selected as ... an online information and news publication for resellers of ... consecutive year Loffler has earned this prestigious award and ... Dealer Awards honor the best and the brightest in ... honorees were chosen for their innovative marketing and sales ...
(Date:11/26/2014)... Senior Planning Services, providing “expert guidance ... organization providing the adult demographic education and access ... navigate the rough seas of applying for Medicaid. Part ... the topic of Medicaid eligibility and proper planning, while ... applying for this coverage. , Senior Planning Services ...
(Date:11/26/2014)... Call 866-997-4948 (Us-Canada Toll Free) Tel: ... details on sales(at)researchmoz(dot)us , Researchmoz.us announces a new ... 2014" with deep study of the report on the ... blood sugar. The global glucose monitoring market has a ... number of diabetics in the world. Their numbers have ...
(Date:11/26/2014)... Rouge, Louisiana (PRWEB) November 26, 2014 ... neck pain relief and specialists in minimally invasive ... K. Samer Shamieh into the rapidly growing provider ... specialists. The addition coincides with the network’s ... reliable medical treatment for Louisiana residents who are ...
(Date:11/26/2014)... (HealthDay News) -- Youngsters who enter puberty early are ... Early puberty was linked with a number of ... high anxiety levels, according to the researchers. Early puberty ... with family and peers, and having friends who were ... Although the study found an association between early puberty ...
Breaking Medicine News(10 mins):Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2
... an efficient, effective way to analyze wounds from bullets and ... the March issue of Radiology . "The ... care and aid in both military and civilian forensic investigations," ... from the Uniformed Services University in Bethesda, Md. U.S. ...
... Extremely obese people had a significantly greater chance of dying ... that became a pandemic last winter, a new study reports. ... with H1N1 flu during the first four months of 2009 ... three-fold increased risk for death. Extreme obesity is defined ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, Jan. ... the risk of autism in the second child, new research ... within a year of their older sibling. Babies conceived within ... their older sibling were also at a heightened risk of ...
... HealthDay Reporter , MONDAY, Jan. 10 (HealthDay News) -- Widespread ... a 5 percent drop in available nursing home beds across ... research reveals. "The country,s minority population is aging at ... lead author Zhanlian Feng, an assistant professor of community health ...
... is well known that pain is a highly subjective experience. ... depending on distractions and mood. A paper in the ... cautionary note on measuring perceived pain in research. There ... symptoms other than pain, but because of the subjectivity in ...
... report a gene therapy strategy that improves the condition ... Beta Thalassemia. The gene correction involves using unfertilized ... embryonic stem cell lines. Some of these stem cell ... thus be used for transplantation-based treatments of the same ...
Cached Medicine News:Health News:CT helps identify bullet trajectories 2Health News:Closely Spaced Pregnancies Might Up Autism Risk: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 3Health News:Does it hurt? 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: